SG11202111476RA - Peptides in combination with immune checkpoint inhibitors for use in treatment of cancer - Google Patents

Peptides in combination with immune checkpoint inhibitors for use in treatment of cancer

Info

Publication number
SG11202111476RA
SG11202111476RA SG11202111476RA SG11202111476RA SG11202111476RA SG 11202111476R A SG11202111476R A SG 11202111476RA SG 11202111476R A SG11202111476R A SG 11202111476RA SG 11202111476R A SG11202111476R A SG 11202111476RA SG 11202111476R A SG11202111476R A SG 11202111476RA
Authority
SG
Singapore
Prior art keywords
peptides
cancer
treatment
combination
immune checkpoint
Prior art date
Application number
SG11202111476RA
Inventor
Peter Johannes Holst
Lena Axelsson
Tommy Andersson
Original Assignee
Wntresearch Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wntresearch Ab filed Critical Wntresearch Ab
Publication of SG11202111476RA publication Critical patent/SG11202111476RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
SG11202111476RA 2019-04-16 2020-04-16 Peptides in combination with immune checkpoint inhibitors for use in treatment of cancer SG11202111476RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19169388 2019-04-16
PCT/EP2020/060750 WO2020212514A1 (en) 2019-04-16 2020-04-16 Peptides in combination with immune checkpoint inhibitors for use in treatment of cancer

Publications (1)

Publication Number Publication Date
SG11202111476RA true SG11202111476RA (en) 2021-11-29

Family

ID=66217724

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202111476RA SG11202111476RA (en) 2019-04-16 2020-04-16 Peptides in combination with immune checkpoint inhibitors for use in treatment of cancer

Country Status (10)

Country Link
US (1) US20220202901A1 (en)
EP (1) EP3955950A1 (en)
JP (1) JP2022529434A (en)
KR (1) KR20220050835A (en)
CN (1) CN113939305A (en)
AU (1) AU2020259121A1 (en)
BR (1) BR112021020635A2 (en)
CA (1) CA3137093A1 (en)
SG (1) SG11202111476RA (en)
WO (1) WO2020212514A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112023025148A2 (en) * 2021-06-01 2024-02-27 Wntresearch Ab WNT5A PEPTIDE OR ITS DERIVATIVES, WNT5A PEPTIDE OR ITS DERIVATIVES IN COMBINATION WITH A CHEMOTHERAPEUTIC DRUG OR BLOOD TRANSFUSION, AND, USES
WO2024038051A1 (en) * 2022-08-15 2024-02-22 Wntresearch Ab Prevention of tumour proliferation and growth

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1888628B1 (en) * 2005-05-30 2014-11-12 Wntresearch AB A peptide ligand to impair cancer cell migration
EP2280994A4 (en) * 2008-04-30 2011-05-25 Wntres Ab Restoration of estrogen receptor-alpha activity
KR101085602B1 (en) * 2009-01-08 2011-11-22 서울대학교산학협력단 Screening methods for anticancer agents by using ROR?
EP2726880B1 (en) * 2011-07-01 2019-04-17 Wntresearch AB Treatment of prostate cancer and a method for determining the prognosis for prostate cancer patients
EP3229831B1 (en) * 2014-12-10 2020-03-11 Hyperstem SA Methods and compositions for reducing growth, migration and invasiveness of brain cancer stem cells and improving survival of patients with brain tumors
US20180244783A1 (en) * 2015-08-31 2018-08-30 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease

Also Published As

Publication number Publication date
BR112021020635A2 (en) 2022-02-22
US20220202901A1 (en) 2022-06-30
KR20220050835A (en) 2022-04-25
CN113939305A (en) 2022-01-14
CA3137093A1 (en) 2020-10-22
WO2020212514A8 (en) 2021-12-09
AU2020259121A1 (en) 2021-11-25
JP2022529434A (en) 2022-06-22
EP3955950A1 (en) 2022-02-23
WO2020212514A1 (en) 2020-10-22

Similar Documents

Publication Publication Date Title
IL283908A (en) Method of treating cancer with an immune checkpoint inhibitor in combination with another therapeutic agent
SG11201706681VA (en) Novel peptides and combination of peptides for use in immunotherapy against various tumors
SG10202101368WA (en) Novel peptides and combination of peptides for use in immunotherapy against various cancers
IL248507A0 (en) Combination therapy for treating cancer with a recombinant poxvirus expressing a tumor antigen and an immune checkpoint molecule antagonist or agonist
SG10202001404VA (en) Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
GB201511792D0 (en) Novel peptides and combination of peptides for use in immunotherapy against esopageal cancer and other cancers
IL251761B (en) A combination of alpha thymosin peptide and pd-1 inhibitor useful in treating cancer
SG11202010212RA (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
HK1246181A1 (en) Novel peptides and combination of peptides for use in immunotherapy against various tumors
IL288728A (en) Anti-sortilin antibodies for use in therapy
EP3888648A4 (en) Treatment of cancer by combination of immune checkpoint inhibitor and folfirinox therapy
IL280830A (en) Conjugates for use in methods of treating cancer
IL292143A (en) Alkylesters of alpha-methyl-dl-tyrosine for use in treating cancer
IL280879A (en) Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
SG11202111476RA (en) Peptides in combination with immune checkpoint inhibitors for use in treatment of cancer
PL3294279T3 (en) Compositions comprising amino acids for use in the treatment of mucositides in neoplasia patients undergoing radiation therapy and/or chemotherapy
DK3463436T3 (en) VACCINE IN COMBINATION WITH AN IMMUNE CHECKPOINT INHIBITOR FOR USE IN THE TREATMENT OF CANCER
GB201702160D0 (en) Inhibitors for use in therapy
IL266116A (en) Anti-bag3 antibodies in combination with inhibitors of immune check-point for therapeutic use
HK1255541A1 (en) Novel peptides and combination of peptides for use in immunotherapy against various cancers
ZA202007955B (en) Ccr5 inhibitor for use in treating cancer
IL273092A (en) Hdac inhibitor in combination with immune checkpoint modulator for cancer therapy
IL283687A (en) Usp19 inhibitors for use in therapy
IL284320A (en) Tim-3 antibodies and combinations with other checkpoint inhibitors for the treatment of cancer
SG11202105276TA (en) Oligo-benzamide analogs and their use in cancer treatment